Your browser doesn't support javascript.
loading
Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.
Beelen, Nicky A; Ehlers, Femke A I; Bos, Gerard M J; Wieten, Lotte.
Afiliação
  • Beelen NA; Department of Transplantation Immunology, Maastricht University Medical Center+, P. Debeyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
  • Ehlers FAI; GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
  • Bos GMJ; Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Wieten L; Department of Transplantation Immunology, Maastricht University Medical Center+, P. Debeyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Cancer Immunol Immunother ; 72(4): 797-804, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36261539
ABSTRACT
Natural killer (NK) cells mediate potent anti-tumor responses, which makes them attractive targets for immunotherapy. The anti-tumor response of endogenous- or allogeneic NK cells can be enhanced through clinically available monoclonal antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC). NK cell activation is regulated by interaction of inhibitory receptors with classical- and non-classical human leukocyte antigens (HLA) class I molecules. Inhibitory receptors of the killer immunoglobulin-like receptor (KIR) family interact with HLA-A, -B or -C epitopes, while NKG2A interacts with the non-classical HLA-E molecule. Both types of inhibitory interactions may influence the strength of the ADCC response. In the present review, we provide an overview of the effect of inhibitory KIRs and NKG2A on NK cell-mediated ADCC, which highlights the rationale for combination strategies with ADCC triggering antibodies and interference with the NK cell relevant inhibitory immune checkpoints, such as KIR and NKG2A.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Neoplasias Limite: Humans Idioma: En Revista: Cancer Immunol Immunother Assunto da revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Neoplasias Limite: Humans Idioma: En Revista: Cancer Immunol Immunother Assunto da revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda